Saralasin

Summary

Saralasin is a synthetic peptide that blocks the angiotensin II type 1 (AT1) receptor. Developed as an intravenous agent, it was investigated for acute blood‑pressure reduction in essential hypertension and for haemodynamic improvement in congestive heart failure. Although it demonstrated efficacy in early clinical studies, the compound was later withdrawn and is now used only as a research tool to probe the renin‑angiotensin system.

Mechanism of Action

Saralasin competes with endogenous angiotensin II for binding to the AT1 receptor on vascular smooth‑muscle and adrenal cells, preventing the peptide’s vasoconstrictive and aldosterone‑stimulating actions. As a peptide analogue, it can display partial agonist activity, but overall it functions as an antagonist that blunts the downstream signaling cascade involving phospholipase C, intracellular calcium rise, and vasoconstriction.

What the Research Shows

Early clinical work showed that intravenous saralasin acutely lowered blood pressure in a large proportion of patients with essential hypertension and improved haemodynamics in some with congestive heart failure (Clin Exp Hypertens 1993). It was also employed as a probe to distinguish renin‑mediated versus renin‑independent mechanisms of diastolic hypertension, with the hypotensive response to saralasin serving as an indicator of renin system activity (Laragh 1988, 1987). Historical reviews note that peptide antagonists like saralasin clarified the role of the renin‑angiotensin system in hypertension and heart failure, but later non‑peptide agents (e.g., losartan) were preferred because they lack agonist activity. The compound is currently classified as withdrawn and is used only in experimental settings.

Reported Benefits

Evidence from the 1993 study indicates that saralasin can produce rapid, dose‑dependent reductions in blood pressure in essential hypertension and may improve cardiac output in heart‑failure patients. Its utility as a diagnostic tool lies in its ability to reveal renin‑dependent hypertension, as the blood‑pressure response to saralasin correlates with plasma renin activity, aiding pathophysiologic classification of hypertensive patients.

Limitations of the Evidence

Saralasin was withdrawn and never achieved regulatory approval for chronic therapy. Its peptide nature limits administration to the intravenous route and may provoke partial agonist effects, reducing selectivity compared with later non‑peptide AT1 blockers. The clinical data are confined to short‑term studies from the 1980s‑1990s; long‑term efficacy, safety, and comparative outcomes versus ACE inhibitors or modern ARBs remain unestablished.

Safety Considerations

The abstracts do not detail specific adverse events, but intravenous angiotensin‑II blockade can cause hypotension, dizziness, and reflex tachycardia. Because saralasin retains some agonist activity, unexpected vasoconstriction or aldosterone release may occur in certain settings. Caution is advised in patients with volume depletion or severe renal impairment, and monitoring of blood pressure is essential during infusion.

How It Is Administered

Saralasin is administered intravenously as a peptide solution. It is used acutely in a clinical or research setting; no oral formulation or chronic dosing regimen is described in the literature.

Routes of Administration

Goals & Uses

• Research tool for RAS characterizationResearchHigh
• Antihypertensive effect in high-renin statesCardiovascularModerate
• Diagnosis of renin-dependent hypertensionDiagnosticModerate
• Angiotensin receptor blockadeDiagnosticModerate

Contraindications

• Low-renin hypertension or normal renin statesCardiovascularHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Sodium depletionMetabolicModerate
• Severe hypotensionCardiovascularHigh

Adverse Effects

• HypotensionCardiovascularCommonLow blood pressure
• FlushingVascularUncommonWarmth and redness of the skin
• TachycardiaCardiovascularUncommonAbnormally fast heart rate
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Hypertension (paradoxical)CardiovascularCommon

Drug Interactions

• Other vasodilators (e.g., nitroglycerin)Moderate
• ACE inhibitorsModerate
• DiureticsModerateMay worsen dehydration or electrolyte imbalance

Population Constraints

• Pediatric patientsAgeRelative
• Patients with normal or low renin activityCardiovascularAbsolute
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization in the European Union.
• United StatesUnapprovedInvestigational peptide; not FDA‑approved.
• United KingdomUnapprovedNot licensed for clinical use.

Not approved for therapeutic use in any jurisdiction; employed in research protocols and occasional diagnostic challenge tests.

Evidence & Sources

• Angiotensin II antagonists
  Journal ArticleModerateBrunner HR, et al.1993-01-01T00:00:00.000000Z
• Pathophysiology of diastolic hypertension
  Journal ArticleModerateLaragh JH1988-01-01T00:00:00.000000Z
• Two forms of vasoconstriction in systemic hypertension
  Journal ArticleModerateLaragh JH1987-01-01T00:00:00.000000Z
• [Polypeptides and antagonists]
  Journal ArticleModerateRegoli D1984-01-01T00:00:00.000000Z
• The preclinical basis of the therapeutic evaluation of losartan
  Journal ArticleModerateTimmermans PB, et al.1995-01-01T00:00:00.000000Z
• Blockade of the renin-angiotensin system
  Journal ArticleModerateNicholls MG, et al.1994-01-01T00:00:00.000000Z

Frequently Asked Questions